floxuridine has been researched along with Ovarian Neoplasms in 31 studies
Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "It is well-known that breast cancer easily metastasizes to the bone, liver, pleura and lymph node, but rarely to the ovarium or peritoneum when chemotherapy is conducted." | 5.33 | [Weekly paclitaxel administration and intraabdominal CBDCA injection possibly beneficial treatment for recurrent breast cancer associated with metastatic ovarian cancer and peritoneal dissemination after operation--a case report]. ( Deguchi, Y; Kamimura, K; Kaneko, I; Kii, E; Murata, T; Nonogaki, H; Tanaka, T; Tsubono, M; Yasumizu, R, 2005) |
| " 5-Fluorouracil (5-FU) was effective against only one bladder cancer xenograft among 6 cancer xenografts tested." | 3.68 | [Comparative studies on the antitumor activity of fluorinated pyrimidine derivatives against human bladder, cervical and ovarian cancer xenografts in nude mice]. ( Adachi, S; Akaza, H; Ishitsuka, H; Kanazawa, K; Miwa, M; Nitta, K; Sekiguchi, F; Tokita, H, 1991) |
| "In this series confined to patients with minimal residual disease after initial therapy subjected to second-line intraperitoneal treatment, it appears to identify a poor prognostic (positive) subset for survival." | 2.70 | Correlation of p53 immunostaining in primary and residual ovarian cancer at the time of positive second-look laparotomy and its prognostic role: a Southwest Oncology Group ancillary study. ( Alberts, DS; Belt, RJ; Cote, R; Felix, J; Hawes, D; Liu, PY; Muggia, FM; Terada, K; Wilczynski, S, 2002) |
| " As a result, the extent of toxicity of cancer chemotherapy varies by 50% or more according to dosing time in mice or rats." | 2.68 | [Chrono-chemotherapy and dose intensity]. ( Lévi, F, 1995) |
| "Therapy of metastatic bladder cancer with doxorubicin-cisplatin was made more tolerable by this same circadian approach resulting in a 57% objective response rate." | 2.41 | Circadian chemotherapy for gynecological and genitourinary cancers. ( Hrushesky, WJ; Kobayashi, M; Wood, PA, 2002) |
| "Postoperatively cecal cancer was detected." | 2.39 | [Peritoneal dissemination of cecal cancer disappearing in a patient taking 5'-DFUR for 3 years]. ( Etoh, T; Maeda, Y; Matoba, N; Nagata, T; Niiyama, H; Yoshida, J, 1994) |
| "Among 62 patients with ovarian cancer enrolled in IP platinum doublet studies in clinical trials (with etoposide (n = 18), with floxuridine (n = 30), and with topotecan (n = 14)), a deleterious BRCA mutation was eventually identified in 10 patients." | 1.40 | Ovarian cancer in BRCA mutation carriers: improved outcome after intraperitoneal (IP) cisplatin. ( Curtin, J; Downey, A; Edwards, S; Kwa, M; Muggia, F; Reich, E; Wallach, R, 2014) |
| " Taken together, these studies 1) identify DNA repair and checkpoint pathways that are important in ovarian cancer cells treated with FdUrd, ABT-888, and F+A, 2) show that disabling HR at the level of ATR, BRCA1, BRCA2, or RAD51, but not Chk1, ATM, PTEN, or FANCD2, sensitizes cells to ABT-888, and 3) demonstrate that even though ABT-888 sensitizes ovarian tumor cells with functional HR to FdUrd, the effects of this drug combination are more profound in tumors with HR defects, even compared with other chemotherapy + ABT-888 combinations, including cisplatin + ABT-888." | 1.38 | Identification of DNA repair pathways that affect the survival of ovarian cancer cells treated with a poly(ADP-ribose) polymerase inhibitor in a novel drug combination. ( Huehls, AM; Huntoon, CJ; Karnitz, LM; Wagner, JM, 2012) |
| "It is well-known that breast cancer easily metastasizes to the bone, liver, pleura and lymph node, but rarely to the ovarium or peritoneum when chemotherapy is conducted." | 1.33 | [Weekly paclitaxel administration and intraabdominal CBDCA injection possibly beneficial treatment for recurrent breast cancer associated with metastatic ovarian cancer and peritoneal dissemination after operation--a case report]. ( Deguchi, Y; Kamimura, K; Kaneko, I; Kii, E; Murata, T; Nonogaki, H; Tanaka, T; Tsubono, M; Yasumizu, R, 2005) |
| "Higher TP expression was observed in ovarian cancers than in normal ovaries." | 1.32 | [Significance of tissue thymidine phosphorylase and dihydropyrimidine dehydrogenase activities in ovarian cancer]. ( Akimoto, T; Hasegawa, K; Kishimoto, Y; Morimoto, Y; Sawai, T, 2004) |
| "PD-ECGF/TP (10 ng/ml) and ovarian cancer cyst fluids (2% in medium, v/v) stimulated the production of microvessels." | 1.30 | Thymidine phosphorylase activity and prodrug effects in a three-dimensional model of angiogenesis: implications for the treatment of ovarian cancer. ( Collins, WP; Farzaneh, F; Hata, K; Miyazaki, K; Stevenson, DP, 1998) |
| "The overall response rate was 20." | 1.28 | [Phase II study of 5'-DFUR in uterine cervical cancer and ovarian cancer]. ( Ikeda, M; Noda, K; Ochiai, K; Saito, Y; Sato, A; Suzuki, M; Takada, M; Terashima, Y; Yajima, A; Yoshida, K, 1991) |
| "Treatment with doxifluridine at a dosage of 3000 mg/m2 given intravenously for 5 successive days at 3-week intervals led to 6 partial remissions (17%)." | 1.28 | Phase II clinical trial of doxifluridine in patients with advanced ovarian cancer. ( Neijt, JP; ten Bokkel Huinink, WW; van der Burg, ME; van Oosterom, AT; Vermorken, JB; Willemse, PH, 1991) |
| "In uterine cervical cancer, each group of 9 cases administered single dose of 400 mg of 5'-DFUR and 7 cases administered 400 mg of 5'-DFUR 3 times a day continuously for 7 days was investigated." | 1.28 | [Investigation of 5-fluorouracil (5-FU) levels and pyrimidine nucleoside phosphorylase activities in the tissues from patients with uterine cervical and ovarian cancers after oral administration of 5'-DFUR]. ( Hasegawa, K; Ikeda, M; Kinugasa, M; Kobashi, Y; Noda, K; Odagiri, H; Ohiwa, T; Sekiba, K; Takeuchi, K; Watanabe, Y, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (25.81) | 18.7374 |
| 1990's | 11 (35.48) | 18.2507 |
| 2000's | 7 (22.58) | 29.6817 |
| 2010's | 4 (12.90) | 24.3611 |
| 2020's | 1 (3.23) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, P | 1 |
| Wang, G | 1 |
| Wang, Z | 1 |
| Zhang, C | 1 |
| Wang, F | 1 |
| Cui, X | 1 |
| Guo, S | 1 |
| Huang, W | 1 |
| Zhang, R | 1 |
| Yan, D | 1 |
| Kwa, M | 1 |
| Edwards, S | 1 |
| Downey, A | 1 |
| Reich, E | 1 |
| Wallach, R | 1 |
| Curtin, J | 1 |
| Muggia, F | 1 |
| Baehr, CA | 1 |
| Huntoon, CJ | 3 |
| Hoang, SM | 1 |
| Jerde, CR | 1 |
| Karnitz, LM | 3 |
| Huehls, AM | 2 |
| Wagner, JM | 2 |
| Geng, L | 1 |
| Erlichman, C | 1 |
| Patel, AG | 1 |
| Kaufmann, SH | 1 |
| Hawes, D | 1 |
| Liu, PY | 2 |
| Muggia, FM | 4 |
| Wilczynski, S | 1 |
| Cote, R | 1 |
| Felix, J | 1 |
| Terada, K | 1 |
| Belt, RJ | 1 |
| Alberts, DS | 2 |
| Lu, MJ | 1 |
| Sorich, J | 1 |
| Hazarika, M | 1 |
| Kim, M | 1 |
| Del Priore, G | 1 |
| Jacobs, AJ | 1 |
| Chiang, C | 1 |
| Liu, PC | 1 |
| Fusco, E | 1 |
| Curtin, JP | 1 |
| ANSFIELD, FJ | 1 |
| Hsu, LC | 1 |
| Lee, RM | 1 |
| White, RL | 1 |
| Sironi, S | 1 |
| Messa, C | 1 |
| Mangili, G | 1 |
| Zangheri, B | 1 |
| Aletti, G | 1 |
| Garavaglia, E | 1 |
| Vigano, R | 1 |
| Picchio, M | 1 |
| Taccagni, G | 1 |
| Maschio, AD | 1 |
| Fazio, F | 1 |
| Morimoto, Y | 1 |
| Hasegawa, K | 2 |
| Sawai, T | 1 |
| Kishimoto, Y | 1 |
| Akimoto, T | 1 |
| Tsubono, M | 1 |
| Kaneko, I | 1 |
| Kii, E | 1 |
| Tanaka, T | 1 |
| Murata, T | 1 |
| Kamimura, K | 1 |
| Deguchi, Y | 1 |
| Nonogaki, H | 1 |
| Yasumizu, R | 1 |
| Scarabelli, C | 1 |
| Campagnutta, E | 1 |
| Oberfield, RA | 1 |
| VillaSanta, U | 1 |
| Lévi, F | 1 |
| Etoh, T | 1 |
| Yoshida, J | 1 |
| Matoba, N | 1 |
| Niiyama, H | 1 |
| Maeda, Y | 1 |
| Nagata, T | 1 |
| Wallace, DL | 1 |
| O'Toole, RV | 1 |
| Terada, KY | 1 |
| Franklin, EW | 1 |
| Herrer, GW | 1 |
| Goldberg, DA | 1 |
| Hannigan, EV | 1 |
| Jeffers, S | 1 |
| Muderspach, L | 1 |
| Roman, L | 1 |
| Rosales, R | 1 |
| Groshen, S | 1 |
| Safra, T | 1 |
| Morrow, CP | 1 |
| Stevenson, DP | 1 |
| Collins, WP | 1 |
| Farzaneh, F | 1 |
| Hata, K | 1 |
| Miyazaki, K | 1 |
| Ueda, M | 1 |
| Fujii, H | 1 |
| Yoshizawa, K | 1 |
| Kumagai, K | 1 |
| Ueki, K | 1 |
| Terai, Y | 1 |
| Yanagihara, T | 1 |
| Ueki, M | 1 |
| Kobayashi, M | 1 |
| Wood, PA | 1 |
| Hrushesky, WJ | 2 |
| Mathews, CK | 1 |
| Fritze, D | 1 |
| Kern, DH | 1 |
| Drogemuller, CR | 1 |
| Pilch, YH | 1 |
| Noda, K | 2 |
| Ikeda, M | 2 |
| Saito, Y | 1 |
| Yajima, A | 1 |
| Sato, A | 1 |
| Suzuki, M | 1 |
| Terashima, Y | 1 |
| Ochiai, K | 1 |
| Yoshida, K | 1 |
| Takada, M | 1 |
| van Oosterom, AT | 2 |
| ten Bokkel Huinink, WW | 1 |
| van der Burg, ME | 1 |
| Vermorken, JB | 1 |
| Willemse, PH | 1 |
| Neijt, JP | 1 |
| Miwa, M | 1 |
| Sekiguchi, F | 1 |
| Akaza, H | 1 |
| Tokita, H | 1 |
| Nitta, K | 1 |
| Adachi, S | 1 |
| Kanazawa, K | 1 |
| Ishitsuka, H | 1 |
| Watanabe, Y | 1 |
| Takeuchi, K | 1 |
| Kinugasa, M | 1 |
| Sekiba, K | 1 |
| Kobashi, Y | 1 |
| Ohiwa, T | 1 |
| Odagiri, H | 1 |
| de Bruijn, EA | 1 |
| Tjaden, UR | 1 |
| Reeuwijk, HJ | 1 |
| Pinedo, HM | 1 |
| Goodman, HM | 1 |
| Dottino, PR | 1 |
| Kredenster, D | 1 |
| Mark, M | 1 |
| Runowicz, C | 1 |
| Cohen, CJ | 1 |
3 reviews available for floxuridine and Ovarian Neoplasms
| Article | Year |
|---|---|
Intraperitoneal therapy as consolidation for patients with ovarian cancer and negative reassessment after platinum-based chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials, Phase III a | 2003 |
[Peritoneal dissemination of cecal cancer disappearing in a patient taking 5'-DFUR for 3 years].
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Cecal Neoplasms; Female; Floxuridine; Humans; Middle Ag | 1994 |
Circadian chemotherapy for gynecological and genitourinary cancers.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Cycle; Chronotherapy; Circadian Rhythm; | 2002 |
6 trials available for floxuridine and Ovarian Neoplasms
| Article | Year |
|---|---|
Correlation of p53 immunostaining in primary and residual ovarian cancer at the time of positive second-look laparotomy and its prognostic role: a Southwest Oncology Group ancillary study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials | 2002 |
[Chrono-chemotherapy and dose intensity].
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chronobiology | 1995 |
Intraperitoneal mitoxantrone or floxuridine: effects on time-to-failure and survival in patients with minimal residual ovarian cancer after second-look laparotomy--a randomized phase II study by theSouthwest Oncology Group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Female | 1996 |
Phase I/II study of intraperitoneal floxuridine and platinums (cisplatin and/or carboplatin).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carbop | 1997 |
Cancer chronotherapy: a drug delivery challenge.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Circadian Rhythm; Colorectal Neoplasms; Drug | 1990 |
Continuous infusion fluoropyrimidines as salvage therapy for patients with advanced ovarian carcinoma.
Topics: Adult; Aged; Cyclophosphamide; Female; Floxuridine; Fluorouracil; Humans; Infusions, Intravenous; Mi | 1988 |
22 other studies available for floxuridine and Ovarian Neoplasms
| Article | Year |
|---|---|
Floxuridine-chlorambucil conjugate nanodrugs for ovarian cancer combination chemotherapy.
Topics: Antineoplastic Agents; Chlorambucil; Drug Therapy, Combination; Female; Floxuridine; Humans; Nanopar | 2020 |
Ovarian cancer in BRCA mutation carriers: improved outcome after intraperitoneal (IP) cisplatin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Carboplatin; Cis | 2014 |
Glycogen Synthase Kinase 3 (GSK-3)-mediated Phosphorylation of Uracil N-Glycosylase 2 (UNG2) Facilitates the Repair of Floxuridine-induced DNA Lesions and Promotes Cell Survival.
Topics: Antimetabolites, Antineoplastic; Cell Nucleus; Cell Survival; DNA Glycosylases; DNA Repair; DNA Repl | 2016 |
Poly(ADP-Ribose) polymerase inhibition synergizes with 5-fluorodeoxyuridine but not 5-fluorouracil in ovarian cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Benzimidazoles; | 2011 |
Identification of DNA repair pathways that affect the survival of ovarian cancer cells treated with a poly(ADP-ribose) polymerase inhibitor in a novel drug combination.
Topics: Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Benzimidazoles; Cell Cycle Checkpoint | 2012 |
A LESS TOXIC FLUOROURACIL DOSAGE SCHEDULE.
Topics: Alopecia; Breast Neoplasms; Colonic Neoplasms; Diarrhea; Drug Eruptions; Epistaxis; Female; Floxurid | 1964 |
The HPV16 E6/E7 oncogene sensitizes human ovarian surface epithelial cells to low-dose but not high-dose 5-FU and 5-FUdR.
Topics: Apoptosis; Cell Line, Tumor; Dose-Response Relationship, Drug; Epithelial Cells; Female; Floxuridine | 2004 |
Integrated FDG PET/CT in patients with persistent ovarian cancer: correlation with histologic findings.
Topics: Adult; Aged; Female; Floxuridine; Humans; Middle Aged; Ovarian Neoplasms; Positron-Emission Tomograp | 2004 |
[Significance of tissue thymidine phosphorylase and dihydropyrimidine dehydrogenase activities in ovarian cancer].
Topics: 5'-Nucleotidase; Adenocarcinoma, Scirrhous; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineo | 2004 |
[Weekly paclitaxel administration and intraabdominal CBDCA injection possibly beneficial treatment for recurrent breast cancer associated with metastatic ovarian cancer and peritoneal dissemination after operation--a case report].
Topics: Adenocarcinoma, Scirrhous; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 2005 |
Intraarterial infusion chemotherapy in the treatment of liver metastases from ovarian cancer.
Topics: Antineoplastic Agents; Cystadenocarcinoma; Doxorubicin; Drug Therapy, Combination; Endometriosis; Fe | 1981 |
Intra-arterial infusion in tumors of the pelvis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality T | 1983 |
Cyclophosphamide and floxuridine adjuvant chemotherapy for stage III and IV carcinoma of the ovary.
Topics: Cyclophosphamide; Cystadenocarcinoma; Cystadenoma; Drug Therapy, Combination; Female; Floxuridine; H | 1980 |
Thymidine phosphorylase activity and prodrug effects in a three-dimensional model of angiogenesis: implications for the treatment of ovarian cancer.
Topics: Adult; Animals; Antineoplastic Agents; Female; Floxuridine; Humans; Isomerism; Microcirculation; Neo | 1998 |
Effects of sex steroids and growth factors on invasive activity and 5'-deoxy-5-fluorouridine sensitivity in ovarian adenocarcinoma OMC-3 cells.
Topics: Basement Membrane; Cell Division; Cell Movement; Collagenases; Culture Media, Conditioned; Cystadeno | 1998 |
Effects of thymidine analogs upon growth control in cultured hormone-dependent ray ovary cells.
Topics: Animals; Bromodeoxyuridine; Cell Differentiation; Cell Division; Cell Line; Cell Survival; Culture M | 1975 |
A new micromethod for the detection of HL-A antigens on cultured human tumor cells.
Topics: Adenocarcinoma; Antibody Specificity; Colonic Neoplasms; Culture Techniques; Cytotoxicity Tests, Imm | 1975 |
[Phase II study of 5'-DFUR in uterine cervical cancer and ovarian cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Administration, Oral; Adult; Aged; Antineoplastic Agents; | 1991 |
Phase II clinical trial of doxifluridine in patients with advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents; Drug Evaluation; Female; Floxuridine; Humans; Kidney; Middle Age | 1991 |
[Comparative studies on the antitumor activity of fluorinated pyrimidine derivatives against human bladder, cervical and ovarian cancer xenografts in nude mice].
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Female; Floxuridine; | 1991 |
[Investigation of 5-fluorouracil (5-FU) levels and pyrimidine nucleoside phosphorylase activities in the tissues from patients with uterine cervical and ovarian cancers after oral administration of 5'-DFUR].
Topics: Administration, Oral; Antineoplastic Agents; Female; Floxuridine; Fluorouracil; Humans; Lymph Nodes; | 1991 |
Pharmacology of 5'-deoxy-5-fluorouridine in patients with resistant ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents; Female; Floxuridine; Fluorouracil; Humans; Kinetics; Middle Aged | 1985 |